Drug Trial Radar · NCT05180240
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
Jul 28, 2022
Primary completion
Jan 31, 2025
Study completion Feb 4, 2025
Sponsor
- Lead sponsor
- Cardiol Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis will be screened and, if eligible, randomized within 10 days of the diagnostic CMR to CardiolRx or placebo. CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahydrocannabinol (THC\<5 ppm). The treatment period is 12 weeks; a last follow-up visit is scheduled one week after the last treatment, 13 weeks after randomization. Study assessments include Cardiac Magnetic Resonance imaging (CMR), ECG monitoring, the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Columbia-Suicide Severity Rating Scale (C-SSRS) as well as physical exams and laboratory tests. The primary and secondary outcome parameters are measured by CMR. Additional outcomes include clinical endpoints and changes in inflammatory and biomarkers.
Conditions
- Acute Myocarditis
Interventions
CardiolRxDrug
Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Extracellular Volume (ECV)Time frame: 12 weeks post randomization
- Global Longitudinal Strain (GLS)Time frame: 12 weeks post randomization
Locations
37 sites in 5 countries. Site status is shown where the registry gives one.
MedStar Heart and Vascular Institute
Washington D.C., District of Columbia
Massachusetts General Hospital site
Boston, Massachusetts
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota
Cleveland Clinic
Cleveland, Ohio
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Virginia Commonwealth University
Richmond, Virginia
Hospital Felicio Rocho - Fundação Felice Rosso
Belo Horizonte, Brazil
Hospital Angelina Caron
Campina Grande do Sul, Brazil
Hospital São Lucas
Porto Alegre, Brazil
Instituto D´Or de Pesquisa e Ensino
Rio de Janeiro, Brazil
Hospital Pró-Cardíaco
Rio de Janeiro, Brazil
Hospital Regional de São José
São José, Brazil
Irmandade da Santa Casa de Misericórdia de São Paulo
São Paulo, Brazil
Instituto do Coração - InCor
São Paulo, Brazil
Nupec-Orizonti
Belo Horizonte, Minas Gerais, Brazil
PUC trials
Curitiba, Paraná, Brazil
Complexo Hospitalar de Niterói
Niterói, Rio de Janeiro, Brazil
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre (HCPA)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nove de Julho
São Paulo, São Paulo, Brazil
University of Alberta Hospital
Edmonton, Alberta, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Hopital Louis Pradel Hospices Civils de Lyon
Bron, France
CHU de Montpellier
Montpellier, France
Centre Hospitalier Universitaire de Nîmes
Nîmes, France
Hôpital Lariboisière - Département de Cardiologie
Paris, France
Hopital Bichat Claude Bernard
Paris, France
Hôpital européen Georges-Pompidou
Paris, France
Institut de Cardiologie hopital Pitié Salpêtrière
Paris, France
Centre Hospitalier Universitaire de Poitiers
Poitiers, France
Hôpital Foch
Suresnes, France
Chu Rangueil
Toulouse, France
Barzilai Medical Center
Ashkelon, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Beilinson Hospital, Rabin medical Center
Petah Tikva, Israel
Tel Aviv Sourasky Medical Center (Ichilov)
Tel Aviv, Israel
Shamir Medical Center (Assaf Harofeh)
Zrifin, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.